Skip to main content
. 2021 Aug 5;70(12):3679–3692. doi: 10.1007/s00262-021-03024-0

Fig. 5.

Fig. 5

Overall survival in patients with documented disease progression. a Overall survival in 82 patients with documented disease progression treated with GX301 vaccine. b Overall survival in 59 patients with documented disease progression treated with GX301 vaccine and then with either abiraterone acetate, enzalutamide, or cabazitaxel (used singularly or in sequential combination)